Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALC01 in Parkinson's Disease
NCT07212088Phase 1Not yet recruiting
- Sponsor
- iCamuno Biotherapeutics
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial in Parkinson's disease (PD) (2 arms), sponsored by iCamuno Biotherapeutics. Primary endpoint: Treatment-Emergent Adverse Events at 12 months. Planned start Feb 2026; status: not yet recruiting.
02
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07212088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07212088.